Levamisole in rheumatoid arthritis. A randomised double-blind study comparing two dosage regimens of levamisole with placebo. Multicentre study group.
The therapeutic effect of levamisole in patients with rheumatoid arthritis was evaluated in a sixteen-centre double-blind controlled study which compared continuous and intermittent levamisole treatment with placebo for six months. 363 patients with classic or definite rheumatoid arthritis and active disease were evaluated. Continuous and intermittent levamisole treatments were equally effective in controlling disease activity. 20% of patients had important drug-related adverse reactions. The results demonstrated that levamisole is an active drug in patients with rheumatoid arthritis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007391:International Cooperation; D007978:Levamisole / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010919:Placebos; D012107:Research Design; D013997:Time Factors
D010919:Placebos; D007978:Levamisole